Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-927 Combinations in Advanced Solid Tumors
NCT03893955Phase 1Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- May 2019
- Primary completion
- Mar 2027
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 1, open-label trial of giloralimab in solid tumor, triple-negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC) (7 arms), sponsored by AbbVie Inc. Primary endpoints: Objective Response Rate at 2 years, Recommended Phase 2 Dose of ABBV-927 + ABBV-368 at 6 months and 1 more. Started May 2019; status: active, not recruiting.
02
Drugs
giloralimab
03
Conditions
solid tumortriple-negative breast cancer (TNBC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03893955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03893955.